AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7745021 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment (discontinued after 4 and 10 months)
Number of subjects: 15
Study 1904090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose and total parenteral nutrition with insulin
Number of subjects: 24
Study 1904090 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous therapy alone
Number of subjects: 24
Study 7440748 — intervention group
Group type: EXPERIMENTAL
Intervention: Child modulator intervention for a 6‐month period
Number of subjects: 90
Study 7440748 — intervention group
Group type: EXPERIMENTAL
Intervention: School informed group (teachers' ratings and achievement test scores)
Number of subjects: 90
Study 7440748 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 90
Study 7440748 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing between modulated and school informed group
Number of subjects: 90
Study 31876896 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 2110
Study 31876896 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 2110
Study 31876896 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab and Docetaxel
Number of subjects: 2110
Study 30657228 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a paediatric specialist for treatment planning
Number of subjects: 788
Study 30657228 — intervention group
Group type: COMPARATOR
Intervention: Responsibility to treat cFPM
Number of subjects: 788
Study 30657228 — intervention group
Group type: COMPARATOR
Intervention: Restoration of cFPM including root canal treatment
Number of subjects: 788
Study 30657228 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of cFPM
Number of subjects: 788
Study 27673579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and cytarabine (FA)
Number of subjects: 45
Study 27673579 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (HD-Ara-C)
Number of subjects: 45
Study 25936545 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Re‐engagement Cue to Action Trigger Tool (CRCATT)
Number of subjects: 77
Study 25936545 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 77
Study 23307029 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 8
Study 23307029 — intervention group
Group type: COMPARATOR
Intervention: Conventional strength training (CON)
Number of subjects: 8
Study 22289530 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 4 ng/ml
Number of subjects: 96
Study 22289530 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 6 ng/ml
Number of subjects: 96
Study 22289530 — intervention group
Group type: COMPARATOR
Intervention: Control group (Remifentanil 0 ng/ml)
Number of subjects: 96
Study 19539256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 97
Study 19539256 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study 17132474 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin for 6 months or less
Number of subjects: 2878
Study 15033948 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5/6 embryo transfer
Number of subjects: 14
Study 11393600 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 0
Study 11393600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep compression
Number of subjects: 0
Study 11393600 — intervention group
Group type: COMPARATOR
Intervention: Placebo desensitization
Number of subjects: 0
Study 9394816 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (fluticasone propionate)
Number of subjects: 0
Study 9394816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9394816 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen challenge
Number of subjects: 0
Study 9394816 — intervention group
Group type: COMPARATOR
Intervention: Hayfever patients (out of season)
Number of subjects: 0
Study 9394816 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 2446064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin, 10 mg i.v. or 40 mg t.i.d. orally
Number of subjects: 0
Study 2446064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin, 10 mg i.v.
Number of subjects: 0
Study 2446064 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine or prazosin pretreatment
Number of subjects: 0
Study 2446064 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine
Number of subjects: 0
Study 29961686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) administered intravenously every 4 weeks (8 or 10 mg/kg based on weight) for 16 weeks, followed by random assignment to TCZ or placebo for 24 weeks.
Number of subjects: 187
Study 29961686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 187
Study 29961686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 27208335 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (AP)
Number of subjects: 30
Study 27208335 — intervention group
Group type: COMPARATOR
Intervention: Parent-managed sensor-augmented pump (SAP)
Number of subjects: 30
Study 25424567 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA) for 20 minutes daily over two weeks
Number of subjects: 10
Study 25424567 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 25424567 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA)
Number of subjects: 10
Study 23663789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity dietary counseling (group A)
Number of subjects: 61
Study 23663789 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 61
Study 23663789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 20051588 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg of 20% mannitol over 15 minutes
Number of subjects: 22
Study 20051588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg of 20% mannitol over 15 minutes
Number of subjects: 22
Study 18164501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (50 mg)
Number of subjects: 40
Study 18164501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17017189 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectification group (80 sides, 64 cases) - anatomical variation dealt with during FESS
Number of subjects: 128
Study 17017189 — intervention group
Group type: COMPARATOR
Intervention: Contrast group (100 sides, 64 cases) - no anatomical variation dealt with during FESS
Number of subjects: 128
Study 14569646 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention to enhance self-efficacy
Number of subjects: 0
Study 10232508 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method for estimating lesion volume
Number of subjects: 20
Study 8908230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (0.3 microgram/kg)
Number of subjects: 14
Study 8908230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal adrenaline (3 micrograms/kg)
Number of subjects: 14
Study 1914761 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily in the morning (N = 104)
Number of subjects: 206
Study 1914761 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at night (N = 106)
Number of subjects: 206
Study 6195235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscrub (chlorhexidine)
Number of subjects: 224
Study 6195235 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated soap
Number of subjects: 224
Study 30947606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 104
Study 30947606 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based corticosteroid injection
Number of subjects: 104
Study 29419692 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 50
Study 26410385 — intervention group
Group type: EXPERIMENTAL
Intervention: BUZZY
Number of subjects: 48
Study 26410385 — intervention group
Group type: COMPARATOR
Intervention: Control (no BUZZY)
Number of subjects: 48
Study 24664349 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g agave inulin
Number of subjects: 29
Study 24664349 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g agave inulin
Number of subjects: 29
Study 24664349 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g agave inulin)
Number of subjects: 29
Study 23011957 — intervention group
Group type: EXPERIMENTAL
Intervention: Various dose levels of the intervention
Number of subjects: 0
Study 23011957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20012022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine/phenylalanine depletion (to reduce DA neurotransmission)
Number of subjects: 16
Study 20012022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (to reduce 5‐HT neurotransmission)
Number of subjects: 16
Study 20012022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan/tyrosine/phenylalanine depletion (to reduce DA and 5‐HT neurotransmission simultaneously)
Number of subjects: 16
Study 20012022 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid control (no depletion)
Number of subjects: 16
Study 18593294 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy
Number of subjects: 0
Study 16098419 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 450
Study 16098419 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 450
Study 12557801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin plus intravaginal misoprostol (n = 36)
Number of subjects: 107
Study 12557801 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin plus placebo intravaginal (n = 34)
Number of subjects: 107
Study 12557801 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol plus intravenous placebo (n = 37)
Number of subjects: 107
Study 12557801 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 107
Study 9602955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine pretreatment
Number of subjects: 12
Study 9602955 — intervention group
Group type: COMPARATOR
Intervention: No famotidine pretreatment (Control)
Number of subjects: 12
Study 8003862 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy
Number of subjects: 0
Study 8003862 — intervention group
Group type: COMPARATOR
Intervention: Extended radical mastectomy
Number of subjects: 0
Study 2591109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha hydroxyvitamin D + calcium + placebo
Number of subjects: 60
Study 2591109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha hydroxyvitamin D + calcium + lynestrenol
Number of subjects: 60
Study 2591109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha hydroxyvitamin D + calcium + sodium fluoride
Number of subjects: 60
Study 2591109 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for sex, age, disease duration and menopausal state)
Number of subjects: 60
Study 30237262 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/dexamethasone
Number of subjects: 0
Study 27599225 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telebehavioral health (HBTBH) via videoconferencing (VC)
Number of subjects: 121
Study 27599225 — intervention group
Group type: COMPARATOR
Intervention: Traditional in-office behavioral activation treatment for depression (BATD)
Number of subjects: 121
Study 24762366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance labor (standing upright with pelvic tilt and hip movements with partner massage for a minimum of 30 minutes)
Number of subjects: 60
Study 24762366 — intervention group
Group type: COMPARATOR
Intervention: Usual care during physiologic labor (Control)
Number of subjects: 60
Study 22094954 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (2 × 450 mg oral valganciclovir/day for 100 days)
Number of subjects: 296
Study 22094954 — intervention group
Group type: COMPARATOR
Intervention: Preemptive therapy (monitored by CMV-PCR, 2 × 900 mg valganciclovir/day for at least 14 days after positive PCR)
Number of subjects: 296
Study 20716330 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 preventive actions implemented by family pediatricians (promotion of breastfeeding, avoidance of solid foods, control of protein intake, avoidance of sugar‐sweetened beverages, avoidance of bottle, active means of transportation, identification of early adiposity rebound, limitation of television viewing, promotion of movement, and teaching portion size) at 10 time points during a 6‐yr follow‐up.
Number of subjects: 3610
Study 20716330 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care provided by family pediatricians.
Number of subjects: 3610
Study 18156412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/d zinc in a liquid supplement
Number of subjects: 0
Study 18156412 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/d zinc in a fortified porridge
Number of subjects: 0
Study 18156412 — intervention group
Group type: COMPARATOR
Intervention: No extra zinc
Number of subjects: 0
Study 17014062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) with methotrexate (MTX)
Number of subjects: 0
Study 17014062 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study 12956243 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard classification learning paradigm with a common stimulus set
Number of subjects: 0
Study 12956243 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape as a relevant dimension in categorization
Number of subjects: 0
Study 12956243 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural language use reflecting stimulus properties
Number of subjects: 0
Study 12956243 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty of mastering classification rules
Number of subjects: 0
Study 11380276 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching protocol only (group 2)
Number of subjects: 97
Study 11380276 — intervention group
Group type: EXPERIMENTAL
Intervention: Active heel raises before stretching (group 3)
Number of subjects: 97
Study 11380276 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial, moist heat to the plantar‐flexor muscles before stretching (group 4)
Number of subjects: 97
Study 11380276 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound for 7 minutes before stretching (group 5)
Number of subjects: 97
Study 11380276 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 97
Study 9211466 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 9
Study 9211466 — intervention group
Group type: EXPERIMENTAL
Intervention: UF-021
Number of subjects: 9
Study 7705376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest
Number of subjects: 10
Study 7705376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral [13C]bicarbonate (0.1 mg kg‐1) during exercise
Number of subjects: 10
Study 7705376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral [13C]bicarbonate (0.1 mg kg‐1) during recovery from exercise
Number of subjects: 10
Study 7705376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest with induced acidosis
Number of subjects: 10
Study 7705376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest with induced alkalosis
Number of subjects: 10
Study 7705376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral [13C]bicarbonate (0.1 mg kg‐1) during acidosis
Number of subjects: 10
Study 7705376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral [13C]bicarbonate (0.1 mg kg‐1) during alkalosis
Number of subjects: 10
Study 3314521 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium, 100 mg by mouth, three times a day
Number of subjects: 29
Study 3314521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2195864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated Fluosol perfusion
Number of subjects: 245
Study 2195864 — intervention group
Group type: COMPARATOR
Intervention: Routine angioplasty
Number of subjects: 245
Study 1098526 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol
Number of subjects: 12
Study 1098526 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 12
Study 1098526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31112371 — intervention group
Group type: EXPERIMENTAL
Intervention: small-spot IMPT
Number of subjects: 35
Study 31112371 — intervention group
Group type: COMPARATOR
Intervention: VMAT
Number of subjects: 35
Study 28735173 — intervention group
Group type: EXPERIMENTAL
Intervention: Detached mindfulness (DM; group treatment, twice weekly)
Number of subjects: 34
Study 28735173 — intervention group
Group type: COMPARATOR
Intervention: Leisure activities (control condition, twice weekly)
Number of subjects: 34
Study 26346941 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI-98854 (25 mg to 75 mg, once daily)
Number of subjects: 102
Study 26346941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26346941 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI-98854
Number of subjects: 102
Study 24093950 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated initiation of renal replacement therapy (within 12 hours of eligibility)
Number of subjects: 100
Study 24093950 — intervention group
Group type: COMPARATOR
Intervention: Standard initiation of renal replacement therapy (monitored over 7 days)
Number of subjects: 100
Study 22030769 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional constipation group (FC)
Number of subjects: 35
Study 22030769 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 19636689 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d orally
Number of subjects: 64
Study 19636689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17257992 — intervention group
Group type: EXPERIMENTAL
Intervention: MECC system (n = 17)
Number of subjects: 40
Study 17257992 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass (n = 23)
Number of subjects: 40
Study 15040515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 908
Study 15040515 — intervention group
Group type: EXPERIMENTAL
Intervention: White European admixture among Hispanics
Number of subjects: 908
Study 15040515 — intervention group
Group type: COMPARATOR
Intervention: White European admixture among non-Hispanic blacks
Number of subjects: 908
Study 15040515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic blacks
Number of subjects: 908
Study 11203770 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite
Number of subjects: 34
Study 11203770 — intervention group
Group type: COMPARATOR
Intervention: Resin-modified glass-ionomer restorative material
Number of subjects: 34
Study 9754450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of alprazolam
Number of subjects: 20
Study 9754450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8154558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sending a reminder postcard
Number of subjects: 0
Study 8154558 — intervention group
Group type: COMPARATOR
Intervention: Mailing the recommendation letter from each woman's primary care physician
Number of subjects: 0
Study 3042939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrease (8 capsules daily)
Number of subjects: 11
Study 3042939 — intervention group
Group type: COMPARATOR
Intervention: Eurobiol (2 bottles daily)
Number of subjects: 11
Study 30912160 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Intervention Problem Solving (TIPS) for 2 months
Number of subjects: 45
Study 30912160 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 45
Study 31450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening adoption stages (pre-contemplation, contemplation, preparation, action, maintenance)
Number of subjects: 334
Study 31450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 334
Study 31450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history of breast cancer
Number of subjects: 334
Study 31450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived susceptibility
Number of subjects: 334
Study 31450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived severity
Number of subjects: 334
Study 31450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of symptoms
Number of subjects: 334
Study 28346719 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis Bb‐12, Lactobacillus acidophilus La‐5)
Number of subjects: 415
Study 28346719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 25171898 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt plus probiotic capsules
Number of subjects: 156
Study 25171898 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt plus placebo capsules
Number of subjects: 156
Study 25171898 — intervention group
Group type: COMPARATOR
Intervention: Control milk plus probiotic capsules
Number of subjects: 156
Study 25171898 — intervention group
Group type: COMPARATOR
Intervention: Control milk plus placebo capsules
Number of subjects: 156
Study 21883985 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 80
Study 21883985 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles with Bangerter filters
Number of subjects: 80
Study 21150558 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted protease inhibitors (any of the regimens including LPV/r)
Number of subjects: 3719
Study 21150558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonboosted protease inhibitors
Number of subjects: 3719